Eli Lilly says it has applied for full FDA approval of its Alzheimer’s treatment, donanemab, and expects the agency to make a decision by the end of the year. CEO David Ricks joins SquawkStreet to discuss.
Almost half of patients – 47% – who received donanemab showed no disease progression a year after treatment began, according to the final trial results. That compares with 29% for those who did not receive the drug.
"The results illustrate that initiating treatment as early as possible enables the possibility of a bigger beneficial effect, but also that there is potential for slowing of disease progression even when treatment is started later in the disease progression," said Maria Carrillo, chief science officer of the Alzheimer's Association, in a statement.
Donanemab cleared amyloid plaque at six months in 34% of patients who had intermediate levels of a protein called tau, which can become toxic and kill neurons.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Eli Lilly’s experimental Alzheimer’s drug slows disease, data showAn experimental Alzheimer’s drug made by Eli Lilly slowed cognitive decline in early-stage patients, data confirmed Monday, putting it on course to be the second treatment approved within months that alters the course of the disease.
Baca lebih lajut »
Second Alzheimer's drug in the pipeline promises to slow worsening but with safety concernAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, according to a study of 1,700 patients. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab.
Baca lebih lajut »
Second Alzheimer’s drug to slow disease’s progression may be approved in the US this year | CNNA second drug may join the Alzheimer’s treatment Leqembi on the market by the end of the year: Eli Lilly’s donanemab. Lilly said in a news release that it had completed its US Food and Drug Administration submission for the drug, and expects regulatory action by year’s end.
Baca lebih lajut »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskAnother experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday. Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer’s treatment convincingly shown to delay the mind-robbing disease — after the recently approved Leqembi from Japanese drugmaker Eisai.
Baca lebih lajut »
Second Alzheimer's drug in pipeline can slow the disease by a few months but with safety riskNew research shows another experimental Alzheimer's drug can modestly slow patients' inevitable worsening.
Baca lebih lajut »
Dear Abby: Is it normal for people to ignore relatives who have Alzheimer’s?Dad got along with everyone. So I’m left with the conclusion that either no one cared, or were afraid to see someone with Alzheimer’s.
Baca lebih lajut »